The FDA released a draft guidance providing nonclinical study recommendations for the development of microdose radiopharmaceutical diagnostic drugs. The draft is intended to provide recommendations for a pathway to marketing authorization, the FDA said in a notice slated for publication in Wednesday's Federal Register. Comments should be submitted by Nov. 12.